Compare MDA & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDA | ABCL |
|---|---|---|
| Founded | 1969 | 2012 |
| Country | Canada | Canada |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.1B |
| IPO Year | 2021 | 2020 |
| Metric | MDA | ABCL |
|---|---|---|
| Price | $29.04 | $11.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 13 |
| Target Price | ★ $41.80 | $18.00 |
| AVG Volume (30 Days) | 753.7K | ★ 3.2M |
| Earning Date | 11-05-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $75,128,000.00 |
| Revenue This Year | $18.41 | N/A |
| Revenue Next Year | $47.69 | $10.03 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 160.56 |
| 52 Week Low | $23.23 | $2.75 |
| 52 Week High | $49.37 | $14.98 |
| Indicator | MDA | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 50.18 | 45.51 |
| Support Level | $28.44 | $10.65 |
| Resistance Level | $29.76 | $13.21 |
| Average True Range (ATR) | 1.60 | 1.00 |
| MACD | 0.26 | -0.06 |
| Stochastic Oscillator | 53.75 | 25.16 |
MDA Space Ltd is a developer and manufacturer of technology and services to the space industry. It is an international space mission partner and robotics, satellite systems, and geo-intelligence pioneer. It is engaged in communications satellites, Earth and space observation, space exploration, and infrastructure. The Company collaborates and partners with governments and space agencies, commercial space companies, and defence and aerospace prime contractors in the space industry. Geographically, it generates the majority of its revenue from Canada.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.